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Antigen derived from engulfed apoptotic cells can be cross-presented by dendritic cells (DCs) for the generation of
major histocompatibility class I/peptide complexes. While the early events of recognition and internalization of the
dying cell have been characterized, the antigen-processing pathway or pathways remain unknown. We established a
mouse model assaying for the activation of polyclonal T cells reactive to antigen derived from apoptotic cells, and
demonstrated two distinct pathways for the trafficking of exogenous epitopes. In the first, exogenous antigen is
dependent on the DC’s expression of a functional transporter associated with antigen processing (TAP). Surprisingly,
we found evidence that a second pathway exists in which transfer of processed antigen from the dying cell allows
formation of major histocompatibility class I/peptide complexes in TAP-deficient DCs. In vivo data suggest that in
situations of stress (e.g., viral infection), this latter pathway may be more efficient, illustrating that dying cells may
preselect immunologically important antigenic determinants.
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Introduction
Apoptosis is considered the primary means by which
physiologic cell death occurs [1]. The fate of apoptotic
material is rapid clearance and degradation by phagocytes.
There is, however, growing evidence that apoptotic death
need not be an endpoint, and that dying cells are capable of
transferring antigen to the immune system for the induction
of T cell immunity [2,3]. We have previously demonstrated
that human dendritic cells (DCs) phagocytose apoptotic cells,
and rather than degrading the internalized material, the DCs
are capable of generating peptide epitopes for major
histocompatibility (MHC) I molecules and activating viral-
and tumor-antigen-speciﬁc CD8
þ T cells [4–6]. This pathway
has been referred to as cross-presentation for its ability to
‘‘cross’’ classically deﬁned restrictions for MHC I antigen
presentation [7]. Our work has offered a physiologically
relevant mechanism for the in vivo phenomenon of cross-
presentation, which accounts for both the cross-priming and
cross-tolerization of tissue-restricted antigen-speciﬁc CD8
þ T
cells [8–10]. We have demonstrated that antigen capture
occurs via receptor-mediated phagocytosis [5,11], and that
internalized apoptotic material can be located within the
MHC II containing compartment [12]; however, the trafﬁck-
ing of antigen from the apoptotic cell to the DC for
generation of MHC I/peptide (MHC I/pep) complexes has
not been fully characterized.
To deﬁne the cellular machinery required for cross-
presentation, several studies have focused on the use of cells
expressing vector-encoded gene products to test whether
proteasomal substrates (e.g., intact proteins) or chaperoned
peptides serve as the source of antigen [13–15]. While these
studies conclude that cellular proteins are the major source
of antigen transferred to the immune system, the inability to
demonstrate transfer of cell-associated antigen, or the lack of
processed antigen within the dying cell, may have skewed the
observed results. In other studies, the use of exogenous
antigen bound to latex beads [16,17], derived from internal-
ized immune complexes [18] or whole protein [19], does not
permit antigen processing to occur prior to capture by an
antigen-presenting cell (APC); therefore, it is not surprising
that these models demonstrate that the phagosome-to-cytosol
pathway is the dominant means by which antigen is trafﬁcked
for processing and presentation onto MHC I.
To examine whether antigen processed within the dying
cell can be transferred to the DC, we designed in vitro and in
vivo experiments to track the activation of polyclonal
inﬂuenza-reactive T cell responses stimulated by DCs cross-
presenting antigen from haplotype-mismatched apoptotic
cells. We report the utilization of two independent pathways
by which internalized antigen may access MHC I within the
DC: in one, the substrate for cross-presentation is whole or
partially degraded protein, which must be further processed
by the DC; and in the other, we ﬁnd evidence for processed
antigen accessing the MHC I pathway of the DC. Concerning
the in vivo presentation of viral antigen, this latter pathway
seems dominant, thus permitting efﬁcient loading of MHC I/
pep complexes by the DC.
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In order to dissect the pathway or pathways by which
antigens derived from apoptotic cells are processed and
presented by DCs, we established in vivo and in vitro systems
that permit monitoring of direct presentation and cross-
presentation of antigen (Protocol S1; Figure S1). Using these
model systems, we tested the hypothesis that dying cells
participate in the processing of antigen for cross-presenta-
tion. To restrict the DCs’ capacity to process antigen, we
employed bone-marrow-derived DCs prepared from mice
deﬁcient in TAP-1. The generation of antigen-speciﬁc MHC I/
pep complexes was assayed based on the ability to stimulate
inﬂuenza-reactive T cells. In all experiments, interleukin-12
(IL-12) was added to the DC/CD8
þT cell cultures to bypass the
requirement for CD4
þ T cell help [8].
To ensure that the inﬂuenza antigens being monitored
required transporter activity for the generation of MHC I/pep
complexes, we directly infected DCs prepared from TAP
 / 
mice (Figure 1). As has previously been reported, no T cell
activation was evident when infected TAP
 /  DCs were
employed (Figure 1A and 1B). Furthermore, we established
that the TAP
 / DCs efﬁciently engulfed apoptotic bodies and
that the kinetics of uptake were similar to those evident in
wild-type (WT) DCs (Figure S2). DCs that had internalized
dying cells were tested for their ability to cross-present
antigen; in contrast to their ability to present antigen via the
‘‘classical’’ MHC I pathway, the TAP
 / DCs were able to cross-
present inﬂuenza antigen derived from MHC-mismatched
apoptotic cells as efﬁciently as WT DCs (Figure 1D and 1E).
To rule out the possibility that transporter activity was simply
being transferred via fusion of membranes between the
Figure 1. TAP
 /  DCs Cross-Present Antigen Derived from Apoptotic Cells
(A and B) Antigen presentation via the endogenous pathway was evaluated in WT DCs and TAP
 /  DCs by directly infecting cells with inﬂuenza
virus and assaying for T cell activation. IFN-c production and T cell precursor frequency were determined using an ELISPOT assay.
(C) To evaluate transfer of TAP activity from the dying cells to DCs, WT or TAP
 / DCs after capture of apoptotic cells were directly infected and
tested for their respective ability to activate CD8
þ T cells via the endogenous pathway.
(D and E) WT DCs (D) or TAP
 /  DCs (E) were co-cultured for 36–48 h with inﬂuenza-infected or uninfected allogeneic cells in the presence of
TNF-a. As above, mature DCs were harvested and assayed for their ability to stimulate inﬂuenza-reactive CD8
þ T cells. To bypass the
requirement for CD4
þ T cell help in the activation of CD8
þ T cells via the exogenous pathway, IL-12 was added to the cultures.
Spot-formingcells(SFCs)per10
6Tcellsarereported.Dataarerepresentativeofthreeexperiments.Valuesareaveragesoftriplicatewellswitherror
bars indicating standard deviation.
DOI: 10.1371/journal.pbio.0030185.g001
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Cross-Presentation of Processed Antigenapoptotic cells and the DC during phagocytosis, we tested
whether TAP
 /  DCs that had previously internalized unin-
fected TAP-expressing apoptotic cells could now present
antigen after direct infection with inﬂuenza (ﬂu-[TAP
 /  DC
x/p 3T3]; Figure 1C). We detected background levels of T cell
activation in these assays as compared to the robust
stimulation observed using inﬂuenza-infected WT DCs
(Figure 1C), arguing against such a mechanism and support-
ing the possibility that TAP
 /  DCs are capturing processed
antigen from apoptotic cells.
To further establish the role for antigen processing in the
dying cell, we generated apoptotic cells that expressed
inﬂuenza proteins but were unable to process the inﬂuenza
viral antigens. Prior to infection with inﬂuenza and the
induction of apoptosis, 3T3 cells were treated with the
proteasome inhibitor lactacystin [20]. We found that the
lactacystin-treated cells expressed levels of inﬂuenza antigen
similar to untreated cells (Figure 2A). The inhibition of
proteasome activity was conﬁrmed functionally using treated
cells as stimulators for HA-reactive T cells restricted to H-2
d,
the MHC haplotype of the dying 3T3 cells (Figure 2B). Parallel
cultures were triggered to undergo apoptosis and were co-
cultured with WT or TAP
 / DCs as described in the Materials
and Methods. Cross-presentation of antigen by the DCs was
evaluated based on the activation of inﬂuenza-reactive CD8
þ
T cells. We found that the lactacystin-treated apoptotic cells
Figure 2. Processed Antigen from the Dying Cell Is Required for MHC I Presentation in TAP
 /  DCs
To generate apoptotic cells lacking processed antigen, lactacystin pretreatment of inﬂuenza-infected H-2
d 3T3 cells was performed. Expression
of inﬂuenza antigen was evaluated by intracellular FACS analysis using inﬂuenza NP mAbs followed by PE-conjugated goat anti-mouse mAb (A).
Expression of MHC I/pep complexes in the lactacystin-treated 3T3 cells was evaluated by monitoring the activation of H-2
d-restricted inﬂuenza
hemagglutanin-reactive T cells. The K
d-restricted immunodominant peptide (HA210–219) derived from hemagglutanin was pulsed onto 3T3 cells
and served as a positive control (B). The inﬂuenza-infected H-2
d 3T3 cells were then induced to undergo apoptosis, and co-cultures were
generated using C57BL/6 WT DCs (C) or TAP
 /  DCs (D). To evaluate T cell activation and expansion, DCs cross-presenting antigen were
cultured with CD8
þ T cells in the presence of IL-12 for 7–8 d. T cells were then harvested and tested for inﬂuenza reactivity in a 20-h IFN-c
ELISPOT. H-2
b EL4 cells with or without inﬂuenza infection served as the stimulators in the ELISPOT assay as above. Data are representative of
two experiments. Values are averages of triplicate wells with error bars indicating standard deviation.
DOI: 10.1371/journal.pbio.0030185.g002
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Cross-Presentation of Processed Antigenwere competent to serve as a source of antigen for WT DCs
(Figure 2C); however, the lack of processed antigen in
lactacystin-treated 3T3 cells prevented cross-presentation
by TAP
 /  DCs (Figure 2D). This result further establishes
that transporter activity is not passed from the dying cell to
the TAP
 /  DC as a result of an ill-deﬁned fusion event.
Instead, it is an active process whereby processed antigen
within the dying cell is being utilized by the DC for the
generation of MHC I/pep complexes.
To determine the importance of antigen access to the
dying cell’s endoplasmic reticulum (ER), we used RMA/s cells,
which are deﬁcient in TAP-2, as a source of inﬂuenza antigen.
These cells express inﬂuenza proteins upon infection (Figure
S3A), but do not facilitate peptide transport into the ER, as
established by their inability to re-stimulate an inﬂuenza-
Figure 3. Transporter Activity Is Required in Either the Apoptotic Cell or
the DC for Efficient Cross-Presentation of Antigen
RMA/S cells were infected with inﬂuenza and irradiated with UVB to
allow for antigen loading and the induction of apoptotic death. Co-
cultures were generated as described in the Materials and Methods
using WT DCs (A) or TAP
 /  DCs (B). DCs were harvested and tested
for their ability to cross-present antigen and activate inﬂuenza-
reactive CD8
þ T cells as measured in a 40-h ELISPOT assay. To
evaluate loading of MHC II, WT DCs and TAP
 / DCs that had
captured apoptotic antigen were tested for their ability to activate
inﬂuenza-reactive CD4þ T cells. Data are representative of four
experiments. Values are averages of triplicate wells with error bars
indicating standard deviation.
DOI: 10.1371/journal.pbio.0030185.g003
Figure 4. Immunization with Apoptotic Cells Results in the Selective
Priming of T Cells Reactive to Processed Antigen
(A and B) C57BL/6 mice were immunized intraperitoneally with 300
HAU of inﬂuenza (A), or 5 3 10
6 infected apoptotic 3T3 cells (B).
After 14 d, splenocytes were harvested, and CD8
þ T cells were
puriﬁed. To assay for the speciﬁcity of these cells, an IFN-c ELISPOT
was performed using the following stimulators: DCs alone or DCs
pulsed with either 1 lMN P 366–374 or 1 lMP A 224–233 peptide.
(C) C57BL/6 mice were immunized intraperitoneally with 5 3 10
6
untreated versus lactacystin-treated inﬂuenza-infected apoptotic 3T3
cells. As above, 14 d after priming, splenocytes were harvested, and
CD8
þ T cells were puriﬁed and assayed for their reactivity to
NP366–374 versus PA224–233. In this experiment, peptide-pulsed EL4
cells were employed as the stimulators. Data are representative of two
experiments. Values are averages of triplicate wells with error bars
indicating standard deviation.
DOI: 10.1371/journal.pbio.0030185.g004
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þ T cell line (Figure S3B). When WT DCs were
employed as the APC, RMA/s served as a source of antigen for
the generation of MHC I/pep complexes (Figure 3A); in
contrast, when TAP
 /  DCs were used, no activation of CD8
þ
T cells was observed (Figure 3B). While the absence of TAP in
both the dying cell and the DC prevented loading of MHC I,
antigen presentation on MHC II was unaffected, as equivalent
stimulation of inﬂuenza-reactive CD4
þ T cells was observed
when using WT or TAP
 /  DCs (Figure 3A and 3B).
Together, these results su g g e s tt h ep r e s e n c eo ft w o
independent pathways by which antigen may be cross-
presented. The ﬁrst is a pathway that requires transporter
activity in the DC—presumably relying on the transport of
exogenous antigen from the phagosome to the cytosol—and
accounts for the requirement for TAP-sufﬁcient DCs to
generate MHC I/pep complexes in conditions where the
peptide is derived from whole or partially degraded protein
that is present within internalized apoptotic lactacystin-
treated 3T3 cells (see Figure 2C) or TAP
 /  RMA/S cells (see
Figure 3B). In the second, the DCs are able to capture
processed antigen present within proteasome- and TAP-
competent dying cells; notably, this latter antigen source may
be cross-presented without a need for further transporter
activity within the DC (see Figure 1E).
To evaluate the in vivo relevance of these ﬁndings, we took
advantage of a recent observation made by Woodland and
colleagues regarding the unique ability of DCs to generate
MHC I peptides derived from the inﬂuenza A/PR/8 acid
polymerase (PA) protein [21]. They demonstrated that while
most cells are capable of processing inﬂuenza A/PR/8
nucleoprotein (NP), only DCs process and present the
epitope PA224–233. We conﬁrmed this result and demonstra-
ted that both epitopes required transporter activity in the
infected DC—in other words, inﬂuenza-infected TAP
 /  DCs
activated neither NP366–374- nor PA224–233-speciﬁc T cells
(data not shown).
We next analyzed the T cell repertoire generated after
priming C57BL/6 (H-2
b) mice with live inﬂuenza versus
inﬂuenza-infected apoptotic 3T3 (H-2
d) cells. Given that the
apoptotic cells express both NP and PA protein, but process
only NP366–374, the in vivo activation of NP366–374- and
PA224–233-speciﬁc T cells would suggest that the DC was
responsible for processing the antigen, whereas a response to
NP366–374 in the absence of a response to PA224–233 would
imply that processed antigen was the preferred source of
antigen for cross-presentation. As reported by Crowe et al.
[21], priming the mice with 300 hemaglutanin units (HAU) of
live inﬂuenza resulted in the activation of both NP366–374- and
PA224–233-reactive T cells (Figure 4A). However, when
apoptotic inﬂuenza-infected 3T3 cells were injected into
naı ¨ve mice, we observed a robust NP366–374-speciﬁc response
and only weak reactivity to PA224–233 (Figure 4B). To examine
whether the response was indeed due to the processing of
antigen within the dying cell, we primed naı ¨ve mice using
lactacystin-treated inﬂuenza-infected 3T3 cells (prepared as
above), and observed a marked reduction in the efﬁciency of
NP366–374-reactive T cell priming (Figure 4C). Similarly, we
demonstrated that infected kidney epithelial cells derived
from b2m-deﬁcient but not TAP
 /  mice were capable of
priming NP366–374-speciﬁc T cells (Figure 5). These data again
highlight the importance of processed antigen within the ER
of the dying cell. In sum, we demonstrated the in vivo
relevance of DCs capturing processed antigen derived from
dying cells for the cross-priming of CD8
þ T cells, and suggest
that in some experimental conditions, this pathway may be
more efﬁcient than the cross-priming of whole protein.
Figure 5. Processed Antigen within the Dying Cell Is Required for
Efficient In Vivo Priming
C57BL/6 mice were immunized intraperitoneally with 300 HAU of
inﬂuenza (A), or 2 3 10
6 infected apoptotic kidney epithelial cells
derived from b2m-deﬁcient (B) or TAP-deﬁcient mice (C). After 14 d,
splenocytes were harvested, and CD8
þ T cells were puriﬁed. To assay
for the speciﬁcity of these cells, an IFN-c ELISPOT was performed
using the following stimulators: EL4 cells alone or EL4 cells pulsed
with either 1 lMN P 366–374 or 1 lMP A 224–233 peptide. Values are
averages of triplicate wells with error bars indicating standard
deviation.
DOI: 10.1371/journal.pbio.0030185.g005
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Several models for antigen cross-presentation have eval-
uated a role for transporter activity, and most report that
COOH terminal processing by the proteasome and utilization
of TAP by the APC is essential [22,23]. This is understandable
when exogenous antigen is derived from internalized
immune complexes [18], antigen-coated latex beads [16,17],
or whole protein [19]. In these instances, there is no ability
for antigen processing to occur in a manner that would
permit loading of DC MHC I in the absence of transporter
activity. With respect to in vitro systems that have reported a
TAP-independent pathway, the antigens successfully pre-
sented seem limited to peptides immediately COOH-terminal
to an ER targeting sequence, or those within secreted or
transmembrane proteins that are processed by still undeﬁned
ER proteases [24,25]. It has also been demonstrated that at
high levels of antigen challenge, it is possible for peptide
epitopes to be generated by Cathepsin S within the
phagolysosome [26].
In this study, we restricted our analysis to physiologically
relevant levels of antigen (all of which require proteasome
processing and TAP activity), and asked whether dying cells
serve as a source of whole protein or whether they may also
participate in antigen presentation by generating processed
antigen that may be transferred to DCs. As has been
previously shown, our data demonstrated that WT DCs can
process antigen from cells that contain whole or partially
processed protein (see Figures 2C and 3A). To assess the
ability of the dying cell to process the antigen, TAP
 /  DCs
were used. Applying this strategy, we identiﬁed the existence
of an antigen cross-presentation pathway that utilizes
proteasome and transporter activity present in the dying cell
(see Figures 1, 2, and 3). Importantly, when lactacystin-treated
or TAP
 /  apoptotic cells were the source of antigen, the
TAP
 /  DCs were no longer capable of cross-presenting
antigen (see Figures 2D and 3B). Furthermore, we demon-
strated activation of CD4
þ T cells in all experimental
conditions, illustrating that DCs indeed captured dying cells
expressing inﬂuenza antigen, even in situations where MHC I
presentation was inhibited. While this in vitro system allowed
us to carefully control the nature of the antigen present in
the dying cells (whole protein or processed antigen) and
permitted us to ensure the transfer of cell-associated protein
to the DCs, we also tested the ability to prime T cells in vivo.
Taking advantage of the differential processing of inﬂuenza
antigen by DCs versus other cell types, we demonstrated that
in situations of direct infection, DCs processed the antigen.
When dying cells were the source of antigen, we observed a
preferential skewing of T cell cross-priming toward the
protein that could be processed by the apoptotic cell.
Lactacystin treatment of the inﬂuenza-infected cell or the
use of TAP
 /  cells conﬁrmed the requirement for protea-
some processing and transporter activity within the dying cell
(see Figures 4 and 5). Furthermore, the ability to cross-prime
inﬂuenza-speciﬁc T cells with b2m-deﬁcient but not TAP-
deﬁcient cells indicated that the antigen was originating from
the ER of the dying cell (see Figure 5). When greater numbers
Figure 6. An Active Role for Apoptotic Cells in the Transfer of Antigen to DCs
We propose that apoptotic cells play an active role through the transfer of processed antigen to DCs for the generation of MHC I/pep complexes.
This pathway may be dominant in the presentation of infectious antigen as the virus may co-opt cellular translational machinery, resulting in
high levels of viral protein, and the upregulation of stress proteins, as well as inducing apoptotic cell death. Defective ribosomal initiation
products chaperoned by HSPs offer a potential source of antigen. Within the DC, HSPs derived from the internalized apoptotic cell may trafﬁc
via a retrograde transport pathway, shuttled to the trans-Golgi and then the ER via binding to KDEL receptors (A). Alternatively, the evidence for
phagosome–ER (PHAGO-ER) fusion and/or the recycling of MHC I from the plasma membrane offers the possibility that processed antigen may
interact directly with the DC’s MHC I (B). As ER chaperones within the phagocytosed cell would be bound to the pool of peptides derived from
newly synthesized proteins, these pathways offer the DC an accurate representation of what occurred immediately prior to death (A and B). At
high concentrations of protein, we also ﬁnd evidence for the DC processing the cross-presented antigen. This likely occurs via a phago–ER-to-
cytosol pathway as has been previously described (C).
DOI: 10.1371/journal.pbio.0030185.g006
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Cross-Presentation of Processed Antigenof apoptotic cells were used (10–503), it was possible to
observe cross-priming of whole or partially degraded protein
(data not shown). Our ﬁndings support the in vitro work
shown here and that of Serna et al. [27]—cross-priming of
inﬂuenza antigen favors the processed antigen within the
dying cell (Figure 6). Indeed, apoptotic cells may play an
active role in antigen presentation through the delivery of
processed antigen, in turn allowing for efﬁcient generation of
MHC I/pep complexes by the DC.
The identiﬁcation of this pathway raises the intriguing
possibility that ER chaperones within the apoptotic cell are
facilitating delivery of peptide epitopes to the DC (see Figure
6 ) .N o t a b l y ,t h eh e a ts h o c kp r o t e i n s( H S P s )G P 9 6a n d
calreticulin have been shown to associate with newly
processed cytosolic-derived epitopes, and when injected in
vivo, they cross-prime cytotoxic T lymphocytes [28–30]. The
recent reports of ER–phagosome fusion [31] suggest that
HSP/peptide complexes may be capable of direct interaction
with the DC’s MHC I; alternatively, HSPs containing a KDEL
motif (Lys-Asp-Glu-Leu) may employ a retrograde transport
pathway to directly access the ER [24]. As ER chaperones
within the phagocytosed cell would be bound to the pool of
peptides derived from newly synthesized proteins [32], they
offer the DC an accurate representation of what was being
translated immediately prior to death. As an interesting
alternative to HSPs, the processed antigen transferred may be
the pool of peptides bound to chromatin [33]. As the nucleus
lacks efﬁcient peptidase activity, antigen may be protected
within the nuclear remnants of an apoptotic body. If this
were occurring, we predict that loading of the MHC I in the
DC would occur in the phagolysosome.
Our ﬁndings are of particular interest when placed in the
context of three recent studies that report that cell-associated
whole protein is the primary source of antigen for cross-
priming [13–15]. We fully appreciate that our study may
reﬂect the choice of a viral model for cross-priming and
acknowledge that the experimental details will inﬂuence the
conclusions. In this light, it is important to consider the
differences between the chosen model systems. In the work of
Shen and Rock [13], lysates prepared from ovalbumin-
transfected cell lines were used as a source of antigen, testing
different subcellular fractions for their ability to prime
animals. This study argues that intact cellular protein, rather
than peptides or HSP/peptide complexes, is the main source
of antigen for cross-presentation. Considering their use of
nitrogen cavitation as the method for disrupting cells, which
has been reported to dissociate antigenic peptides from
HSP70 and GP96 [34,35], it would be expected that the HSPs
within their lysates would indeed be inert. As a result, this
model may have been biased toward the cross-presentation of
whole antigen. Wolkers et al. [15] demonstrated that peptides
present in the secretory domain of nascent proteins are not
efﬁciently cross-presented, while the stable epitope within the
mature protein is indeed transferred to APCs. The in vivo
studies presented seem to be tracking the cross-presentation
of secreted protein, not cell-associated protein. Use of H-2
d3
H-2
b F1 mice to demonstrate cross-presentation from P815
cells supports the requirement for the P815 (H-2
d) to remain
alive. An alternate interpretation of their experiments is that
soluble proteins produced (in large quantities) by growing
tumors resulted in the observed in vivo T cell activation. As a
result, there may have been little opportunity for processed
cell-associated protein to gain access to a DC. Finally, the
study from Norbury et al. [14] reported that proteasome
substrates (rather than peptides) are critical for achieving
antigen transfer for cross-presentation. These studies rely
heavily on the use of lactacystin to inhibit proteasome
activity. However, while they show the persistence of whole
protein, they do not demonstrate that lactacystin prevents
the generation of processed peptides in the experimental
models used. In the studies described herein, 100 lM
lactacystin with a maintenance dose of 1 lM, to inhibit newly
synthesized proteasomes (during infection and antigen
expression), is required to block the generation of peptides
secondary to inﬂuenza infection. Given the possibility of
newly synthesized proteasomes and/or proteasome-independ-
ent processing acting on their artiﬁcial constructs for the
generation of peptide epitopes, it is critical that functional
studies be used to exclude the production of small amounts of
processed antigen.
In sum, while cell-associated whole protein is important in
cross-priming, previous studies have not excluded protea-
some products or HSP/peptide complexes as substrates for in
vivo cross-priming. As shown here, the apoptotic cell may in
fact play a critical role in processing antigen for cross-
presentation, in essence preselecting immunologically im-
portant antigenic determinants. A comprehensive model
accounting for antigen derived from whole protein as well
as processed antigens from apoptotic cells is needed to more
clearly deﬁne the pathways of antigen cross-priming in
physiologic (resting) as well as pathologic (stress) situations.
Materials and Methods
Mice. WT and TAP-1-deﬁcient C57BL/6 mice were purchased
from Jackson Laboratory (Bar Harbor, Maine, United States). In all
experiments, 4- to 6-wk-old female mice were employed.
Antibodies, cell lines, and reagents. All FACS antibodies used in
this study were obtained from BD Biosciences Pharmingen (San
Diego, California, United States); reagents for the ELISPOT assays
were obtained from Mabtech (Stockholm, Sweden). PC3 cells, a
human prostate cancer cell line, were obtained from American Type
Culture Collection (ATCC) (Manassas, Virginia, United States). BALB/
3T3 cells clone A31 (3T3) were obtained from ATCC. RMA/S, a TAP-
deﬁcient T cell lymphoma cell line derived from the Rauscher murine
leukemia virus–induced RBL-5 cell line, was employed [36]. b2m- and
TAP-deﬁcient kidney epithelial cells were derived from organ culture
followed by a 2-wk in vitro expansion. All cell lines were grown in
DMEM containing 10% fetal bovine serum, supplemented with
nonessential amino acids, sodium pyruvate, glutamine, 2b-mercap-
toethanol, and gentamicin (D-10). Human inﬂuenza A/PR/8 was
provided as allantoic ﬂuid from Charles River Laboratories (Wil-
mington, Massachusetts, United States) and used at a 1:3 dilution to
infect PC3, 3T3, or RMA/S cells (1,000 HAU/10
6 cells) or 1:10 dilution
to infect DCs (300 HAU/10
6 cells). Recombinant mouse TNF-a and IL-
12 were obtained from R&D Systems (Minneapolis, Minnesota,
United States).
Preparation of antigen-loaded DCs. Bone-marrow-derived DCs
were prepared as previously described [37]. In brief, bone marrow
obtained from tibia and femurs was lysed of red blood cells and
cultured at a density of 3310
6 cells/well in six-well plates with RPMI
containing 10% fetal bovine serum, nonessential amino acids, sodium
pyruvate, glutamine, 2b-mercaptoethanol, gentamicin (R-10), and in
the presence of GM-CSF (provided by J558L cells transduced with
GM-CSF, used 3% vol/vol). Fresh GM-CSF-supplemented medium was
added to the wells on days 2, 4, and 6. On day 7, DCs were harvested
and plated in fresh wells with or without apoptotic cells. In addition,
a maturation stimulus, 80 ng/ml rmTNF-a, was added. To generate
inﬂuenza-infected apoptotic cells, living cells were ﬁrst infected with
inﬂuenza for 1 h at 37 8C in serum-free medium. To allow for
expression of viral proteins, 3–5310
6 infected cells per well of a six-
well plate were cultured for 5 h at 37 8C. Cells were washed three
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2) in 0.5
ml of PBS, and 0.5 ml of R-10 was added. Cells were allowed to
undergo apoptosis for 8–10 h prior to adding 10
6 immature DCs.
Non-adherent cells were harvested 36 h later, and mature DCs were
puriﬁed to greater than 95% purity using anti-CD11c microbeads
and LS
þcolumns (Miltenyi Biotec, Bergisch Gladbach, Germany). DCs
were monitored by FACS and found to express high levels of I-A
b and
CD40. To generate inﬂuenza-infected DCs, day 9 mature DCs were
infected with inﬂuenza for 1 h at 37 8C in serum-free medium. These
cells were washed three times in serum containing medium, counted,
and used directly.
In vitro cross-presentation studies. Four- to six-week-old mice
were infected intraperitoneally with 200–300 HAU of inﬂuenza A/PR/
8–1976 (Charles River, North Franklin, Connecticut, United States).
After 2–4 wk, CD4
þ and CD8
þ T cells were isolated using MACS
puriﬁcation (Miltenyi Biotec). These cells served as responders in
antigen cross-presentation ELISPOT assays. Stimulators included WT
or TAP
 /  DCs presenting antigen via the endogenous or exogenous
pathway. To achieve a ratio of 30 T cells to one DC, 2 3 10
5 T cells
were added to 6.6 3 10
3 DCs. Cultures were incubated in the plates
for 20–36 h at 37 8C, after which cells were washed out of the
ELISPOT plates using a mild detergent followed by incubation with 1
lg/ml biotin-conjugated a-interferon-c (a-IFN-c) monoclonal anti-
body (mAb) (BD Biosciences Pharmingen, clone XMG1.2). Wells were
then developed using the Vectastain Elite Kit as per manufacturer’s
instructions (Vector Laboratories, Burlingame, California, United
States). Colored spots represent IFN-c-releasing cells and are
reported as spot-forming cells per 10
6 cells. The ELISPOT plate
evaluation was performed in a blinded fashion by an independent
evaluation service (ZellNet Consulting, Fort Lee, New Jersey, United
States) using an automated ELISPOT reader (Carl Zeiss, Thornwood,
New York, United States) with KS Elispot 4.3 software.
In vivo cross-priming studies. Mice were primed intraperitoneally
using inﬂuenza A/PR/8-infected apoptotic cells. Ten to 14 d post-
immunization, spleens were harvested and CD8
þ T cells were isolated
using MACS puriﬁcation (Miltenyi Biotec). A total of 2 3 10
5 T cells
were added to 2 3 10
4 peptide-pulsed DCs or EL4 cells (haplotype-
matched cell line) in the ELISPOT plates, pre-coated with 5 lg/ml of a
primary a-IFN-c mAb (Mabtech, clone AN18). Cultures were
incubated for 20–36 h at 37 8C, and developed as above.
Supporting Information
Figure S1. DC Cross-Presenting Apoptotic Cells Prime CD8
þ T Cells
In Vivo and Serve As Targets for Effector CD8
þ T Cells In Vitro
(A) C57BL/6 mice were immunized intra-footpad with 10
5 DCs cross-
presenting apoptotic, inﬂuenza-infected PC3 cells, or apoptotic
inﬂuenza-infected PC3 cells alone. Six days following this single
immunization, draining lymph nodes were harvested, CD8
þ T cells
were immediately puriﬁed and tested for their ability to respond to
syngeneic stimulator cells with or without antigen in a 20-hr IFN-c
ELISPOT assay. SFCs per 10
6 CD8þ T cells are reported.
(B) As shown in the schematic representation, surface expression of
inﬂuenza-peptide-loaded MHC I by DCs was monitored using a
modiﬁed cytotoxicity assay. After charging the DCs with antigen via
the endogenous or exogenous pathways, they were loaded with
51Cr
and used as targets for previously activated inﬂuenza-speciﬁc
cytotoxic T lymphocytes. This assay is designed to evaluate the
surface expression of MHC I/pep complexes. DCs were loaded via the
exogenous pathway with inﬂuenza-infected allogeneic 3T3 cells (ﬁlled
black squares) or uninfected 3T3 cells (open black squares).
Alternatively, DCs were directly infected, thus presenting antigen
via the endogenous pathway (ﬁlled red squares) or left uninfected
(open red squares). After antigen expression or capture of the
apoptotic material, respectively, DCs were loaded with
51Cr and
tested as targets. After 5 h, supernatants were collected and percent
cytotoxicity was calculated. Percent cytotoxicity = (experimental-
well
51Cr release   spontaneous release)/(total release   spontaneous
release) 3 100.
Found at DOI: 10.1371/journal.pbio.0030185.sg001 (95 KB EPS).
Figure S2. TAP
 /  DCs Efﬁciently Phagocytose Apoptotic Cells
Immature DCs from C57BL/6 WT or TAP-1-deﬁcient (TAP
 / ) mice
were prepared as above and labeled with the PKH-67-GL (green)
ﬂuorescent cell linker (A and B). These cells were next added to PKH-
26-GL-labeled (red) apoptotic cells (ACs) for 7 h at a ratio of one DC
to ﬁve apoptotic cells in the presence or absence of EDTA. FACS
Calibur analysis allowed for the detection of double-positive cells (A),
indicating that the green DCs captured red apoptotic material.
Phagocytosis was calculated as the percent double-positive cells per
total population of DCs (A). Samples of DCs alone and apoptotic cells
alone were used for setting the parameters of the ﬂow cytometer. The
kinetics of phagocytosis were monitored throughout the experiment,
and the percent double-positive cells is reported (B).
Found at DOI: 10.1371/journal.pbio.0030185.sg002 (54 KB PPT).
Figure S3. RMA/s Cells Express but Do Not Present Inﬂuenza Antigen
on MHC I
(A) RMA or RMA/S cells were infected with inﬂuenza and incubated
at 37 8C for 5 h to allow for viral antigen expression. Cells were ﬁxed,
permeabilized, and stained using NP mAbs followed by PE-con-
jugated goat anti-mouse mAb. Analysis was performed on a FACS
Calibur, and histograms are shown.
(B) Infected RMA or RMA/s cells were used as stimulators in an
ELISPOT assay, testing for their ability to stimulate inﬂuenza-reactive
CD8
þT cells. The inﬂuenza A/PR/8 NP366–374 peptide restricted for D
b
was pulsed onto RMA or RMA/s cells and served as a positive control.
Values are averages of triplicate wells with error bars indicating
standard deviation.
Found at DOI: 10.1371/journal.pbio.0030185.sg003 (205 KB EPS).
Protocol S1. DCs Capture Apoptotic Cells and Cross-Present Antigen
to CD8
þ T Cells
Found at DOI: 10.1371/journal.pbio.0030185.sd001 (31 KB DOC).
Accession Numbers
The NCBI Entrez Protein (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=Protein) accession numbers for the gene products discussed
in this paper are inﬂuenza PA (AAA43619), inﬂuenza NP (B36754),
and K
d-restricted immunodominant peptide (HA210–219) derived from
hemagglutanin (NP040980).
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